WHAT IF ONE
GENE

Can change your entire world?

At AVROBIO, we aim to halt or reverse disease with a single dose of gene therapy. Our goal is simple and powerful: We aim to enable individuals with genetic disease to live longer — free from disease progression, free from painful and debilitating symptoms and free from the burden of chronic treatment regimens.

We're striving to deliver freedom for life

Illustration helix

OUR FOCUSA highly personalized therapy

Our investigational gene therapies start with the patient’s own stem cells. We are developing these treatments for several serious lysosomal disorders.

Learn about our areas of focus.

illustration plus sign

OUR APPROACHSolving the challenges of gene therapy

We've spent years developing a state-of-the-art platform to optimize gene therapies. We call it plato™.

Get to know plato™.

This block is broken or missing. You may be missing content or you might need to enable the original module.
This block is broken or missing. You may be missing content or you might need to enable the original module.

Our Views The latest on gene therapy from our expert team

Read our insights

Our News Our latest press releases

Mar 30 2020

AVROBIO Outlines Response to COVID-19 and Current Assessment of Business Impact

Patient identification for clinical trials continues; dosing temporarily paused as clinical trial sites focus on COVID-19 pandemic Essential laboratory and manufacturing activities currently uninterrupted Cash runway into Q2 2022 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 30, 2020-- AVROBIO, Inc.

Read More

Mar 26 2020

AVROBIO to Participate in Upcoming April Investor Conferences

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 26, 2020-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will participate at three upcoming virtual

Read More

Mar 25 2020

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 25, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Read More

See All

Join our team

Work with Us Join our team!

We are all about innovation. Collaboration. Dedication. And a quality we call “smart speed” — moving thoughtfully but with urgency to bring pioneering therapies to individuals living with genetic disease.

Explore careers at AVROBIO

By the numbers

3

countries where we’re conducting clinical trials 

4

disease indications in our pipeline 

30

years of foundational gene therapy science among our management team

ONE
GOAL:

to give individuals with genetic disease freedom for life

You are now leaving AVROBIO’s website.

The third party website to which you will be directed is not affiliated with AVROBIO, and AVROBIO assumes no responsibility for information or statements on third parties’ websites. Thank you for visiting avrobio.com.

Continue to URL Cancel